fig3
![Pretreatment inflammatory indices predict Bevacizumab response in recurrent Glioma](https://image.oaes.cc/dd5ae343-cfb2-49f8-963c-986305c80cde/3577.fig.3.jpg)
Figure 3. Predictive survival ability combining PLR-NLR information: (A) diagram boxes comparing median survival after BVZ administration among the three groups; (B) overall survival from BVZ administration calculated by Kaplan-Meier curves for 31 patients stratified into three groups, namely double positive, double negative, and single positive; (C) overall survival from BVZ administration calculated by Kaplan-Meier curves for 31 patients stratified into a double-positive group and otherwise. BVZ: bevacizumab; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio